| First Author | Wang S | Year | 2017 |
| Journal | Cancer Lett | Volume | 385 |
| Pages | 51-54 | PubMed ID | 27840244 |
| Mgi Jnum | J:237985 | Mgi Id | MGI:5817827 |
| Doi | 10.1016/j.canlet.2016.11.008 | Citation | Wang S, et al. (2017) EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett 385:51-54 |
| abstractText | The third-generation tyrosine kinase inhibitors (TKI), AZD9291 (osimertinib) and CO-1686 (rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M positive non-small cell lung cancer (NSCLC). However, resistance develops rapidly. EGFR C797S mutation was reported to be a leading mechanism of resistance to the third-generation inhibitors. The C797S mutation appears to be an ideal target for overcoming the acquired resistance to the third-generation inhibitors. This review summarizes the latest development on the discovery of a fourth-generation EGFR TKI, EAI045.3. |
